Asthma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older.
- People admitted to an Emergency Department where doctors suspect they are having an acute asthma attack, based on recognised international asthma guidelines (GINA criteria).
- People who, after an initial breathing treatment (nebulised terbutaline, given three times), still show at least one sign that their asthma is not well controlled — such as breathing more than 22 times per minute, a peak flow reading below 50% of their expected normal value, blood oxygen below 95% while breathing room air, or signs of a severe attack (such as only being able to speak in single words, appearing agitated, sitting hunched forward, or using neck and shoulder muscles to help breathe).
- People who are free to make their own decisions and are not under legal guardianship, curatorship, or a relationship of dependence.
- People covered by a French Social Security scheme, either directly or through another person.
- People who have been given clear and honest information about the study and have signed a consent form agreeing to take part.
Who may not be able to join:
- People who had an acute asthma attack in the 30 days before this one.
- People whose asthma attack is thought to be caused by a severe allergic reaction, a collapsed lung, air around the heart, a lung infection, or a blocked area of the lung.
- People showing at least one of these serious warning signs: drowsiness, confusion, or no breath sounds heard by a doctor listening to their chest.
- People where doctors suspect another condition may be causing the breathing difficulty, such as heart failure, a blockage in the throat, or a blood clot in the lungs (confirm with trial site for other conditions).
- People with a significantly reduced level of consciousness (assessed using a standard medical scale) or dangerously low blood pressure.
- People for whom the type of medication used in this trial (a beta-2 adrenergic agonist) is medically unsuitable.
- People with a known allergy or hypersensitivity to terbutaline or any of its ingredients.
- People for whom the oxygen delivery method used in this trial is medically unsuitable (confirm with trial site for specifics).
- People in protected categories, including those under 18, people detained by a judicial or administrative decision, people assessed as highly dependent using a specific French dependency scale (GIR 1 or GIR 2), or adults under any form of legal protection.
- Women who are pregnant or breastfeeding, and women of childbearing age who are not using effective contraception.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Nicolas MARJANOVIC, MD PHD, CHU Poitiers
Phone: 0549441873
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of responding patients one hour after inclusion
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.